OS Therapies Inc (NYSE:OSTX - Get Free Report)'s share price rose 35.3% during mid-day trading on Tuesday . The company traded as high as $6.48 and last traded at $4.71. Approximately 668,717 shares were traded during mid-day trading, an increase of 408% from the average daily volume of 131,554 shares. The stock had previously closed at $3.48.
Analyst Ratings Changes
Several equities research analysts recently weighed in on OSTX shares. Brookline Capital Management upgraded shares of OS Therapies to a "strong-buy" rating in a research note on Thursday, August 22nd. Maxim Group initiated coverage on OS Therapies in a report on Tuesday, November 26th. They issued a "buy" rating and a $8.00 price target on the stock. Finally, EF Hutton Acquisition Co. I raised OS Therapies to a "strong-buy" rating in a research report on Tuesday, September 3rd.
Get Our Latest Analysis on OS Therapies
OS Therapies Stock Down 3.8 %
The stock's 50 day moving average price is $2.64.
Institutional Investors Weigh In On OS Therapies
A hedge fund recently bought a new stake in OS Therapies stock. Virtu Financial LLC acquired a new position in shares of OS Therapies Inc (NYSE:OSTX - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 10,045 shares of the company's stock, valued at approximately $28,000.
About OS Therapies
(
Get Free Report)
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
See Also
Before you consider OS Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OS Therapies wasn't on the list.
While OS Therapies currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
